Rikke Meineche Schmidt1, Rikke Pilmann Laursen2, Signe Bruun1,3, Anni Larnkjaer2, Christian Mølgaard2, Kim F Michaelsen2, Arne Høst1,3. 1. Hans Christian Andersen Hospital for Children and Adolescents, Odense University Hospital, Odense C, Denmark. 2. Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Frederiksberg C, Denmark. 3. Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark.
Abstract
BACKGROUND: Allergic diseases are common and represent a considerable health and economic burden worldwide. We aimed to examine the effect of a combination of two probiotic strains administered in late infancy and early childhood on the development of allergic diseases and sensitization. METHODS: In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a daily mixture of Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis or placebo-starting prior to attending day care. The intervention period was 6 months, and the parents answered web-based questionnaires on allergic symptoms and doctor's diagnosed allergic disease monthly. IgE was measured at baseline and follow-up. RESULTS: A total of 290 participants were randomized: 144 in the probiotic group and 146 in theplacebo group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the incidence of eczema was 4.2% in the probiotic group and 11.5% in the placebo group (P = 0.036). The incidence of asthma and conjunctivitis did not differ between groups, and no children presented with rhinitis. Sensitization was equal in the two groups at intervention start (7.5% and 9.5%, respectively), and two children in each group were sensitized during the intervention. CONCLUSIONS: We observed a significantly lower incidence of eczema in the probiotic group compared to the placebo group. The probiotics were administered in late infancy-prior to attending day care-suggesting a broader window of opportunity using probiotics in the prevention of eczema. The incidence of asthma, rhinitis, conjunctivitis, and sensitization did not differ.
RCT Entities:
BACKGROUND:Allergic diseases are common and represent a considerable health and economic burden worldwide. We aimed to examine the effect of a combination of two probiotic strains administered in late infancy and early childhood on the development of allergic diseases and sensitization. METHODS: In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a daily mixture of Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis or placebo-starting prior to attending day care. The intervention period was 6 months, and the parents answered web-based questionnaires on allergic symptoms and doctor's diagnosed allergic disease monthly. IgE was measured at baseline and follow-up. RESULTS: A total of 290 participants were randomized: 144 in the probiotic group and 146 in the placebo group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the incidence of eczema was 4.2% in the probiotic group and 11.5% in the placebo group (P = 0.036). The incidence of asthma and conjunctivitis did not differ between groups, and no children presented with rhinitis. Sensitization was equal in the two groups at intervention start (7.5% and 9.5%, respectively), and two children in each group were sensitized during the intervention. CONCLUSIONS: We observed a significantly lower incidence of eczema in the probiotic group compared to the placebo group. The probiotics were administered in late infancy-prior to attending day care-suggesting a broader window of opportunity using probiotics in the prevention of eczema. The incidence of asthma, rhinitis, conjunctivitis, and sensitization did not differ.
Authors: Birgit Linhart; Raphaela Freidl; Olga Elisyutina; Musa Khaitov; Alexander Karaulov; Rudolf Valenta Journal: Nutrients Date: 2019-06-29 Impact factor: 5.717
Authors: Joanne R Chalmers; Rachel H Haines; Lucy E Bradshaw; Alan A Montgomery; Kim S Thomas; Sara J Brown; Matthew J Ridd; Sandra Lawton; Eric L Simpson; Michael J Cork; Tracey H Sach; Carsten Flohr; Eleanor J Mitchell; Richard Swinden; Stella Tarr; Susan Davies-Jones; Nicola Jay; Maeve M Kelleher; Michael R Perkin; Robert J Boyle; Hywel C Williams Journal: Lancet Date: 2020-02-19 Impact factor: 202.731